drugset / Trial / NCT00014560
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 1
Terminated
3 enrolled
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of antibody therapy in treating patients who have refractory or relapsed non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Timeline
- Start
- 2000-09-28
- Primary completion
- 2003-02-14
- Completion
- 2003-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 4G7xH22 | Monoclonal antibody | — | Intravenous |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |